Analysts Raise Moderna Price Targets After Q3 Results
Goldman Sachs raised its target to $195 from $137, Piper Sandler to $305 from $230, RBC to $145 from $130 and Jefferies to $230 from $200.
Following Moderna's third-quarter 2026 financial results, multiple analysts updated their price targets for the company. Goldman Sachs raised its price target to $195 from $137, while Piper Sandler increased its target to $305 from $230. Additionally, RBC raised its target to $145 from $130, and Jefferies increased its target to $230 from $200. These adjustments reflect analyst responses to the company's reported revenue growth and updated financial guidance.